According to a study by Lancet, the symptoms of a rare paediatric inflammatory multisystem syndrome(PIMS-TS) associated with SARS-CoV2 are resolved after six months. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) is a type of presentation of SARS-CoV-2 infection that produces a 10 times greater need for hospitalisation and mortality in children than other COVID-19 presentations.
About Paediatric Inflammatory Multisystem Syndrome(PIMS-TS):
PIMS-TS is also known as a multisystem inflammatory syndrome in children (MIS-C). It is a rare condition associated with SARS-CoV-2 infection that was first defined in April 2020.
Caused by: It is not known what triggers the condition. But it is thought to be a rare immune overreaction that occurs in children approximately four to six weeks after mild or asymptomatic SARS-CoV-2 infection.
Symptoms: It includes fever, rash, eye infection, and gastrointestinal symptoms (e.g. diarrhoea, stomach ache, nausea). In some rare cases, the condition can lead to multi-organ failure.
Diagnosis: Currently, MIS-C is diagnosed based on symptoms together with laboratory tests that look for signs of inflammation in the body.
Treatment: Treatments currently include anti-coagulation to curb blood clotting, IV immunoglobulin and anti-inflammatory drugs.
About the Lancet Study:
The Lancet study has been conducted on a small group of children affected with PIMS-TS.
The study has found that most gastrointestinal, heart, and neurological symptoms in children are resolved within six months of the COVID-19 infection.
Moreover, the long-term damage to the organs is thought to be a rare occurrence.